-
1
-
-
0014661330
-
Treatment of multiple myeloma: Combination chemotherapy with different melphalan dose regimens
-
Alexanian R, Haut A, Khan AU, et al. Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1696.
-
(1969)
JAMA
, vol.208
, pp. 1680-1696
-
-
Alexanian, R.1
Haut, A.2
Khan, A.U.3
-
2
-
-
17944381821
-
Increased conventional chemotherapy does not improve survival in multiple myeloma: Long-term results of two PETHEMA trials including 914 patients
-
Bladé J, San Miguel JF, Fontanillas M, et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001; 2:272-278.
-
(2001)
Hematol. J.
, vol.2
, pp. 272-278
-
-
Bladé, J.1
San Miguel, J.F.2
Fontanillas, M.3
-
3
-
-
0344076348
-
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
-
The Myeloma Trialists' Collaborative Group
-
The Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16:3832-3842.
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 3832-3842
-
-
-
4
-
-
0033764086
-
High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution
-
Bladé J, Esteve J, Rives S, et al. High-dose therapy autotransplantation/ intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26:845-849.
-
(2000)
Bone Marrow Transplant
, vol.26
, pp. 845-849
-
-
Bladé, J.1
Esteve, J.2
Rives, S.3
-
5
-
-
0034954989
-
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
-
Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27:1037-1042.
-
(2001)
Bone Marrow Transplant
, vol.27
, pp. 1037-1042
-
-
Alexanian, R.1
Weber, D.2
Giralt, S.3
-
6
-
-
0012961309
-
High-dose therapy and autologous transplantation
-
Mehta J, Singhal S, eds. London: Martin Dunitz
-
Singhal S. High-dose therapy and autologous transplantation. In: Mehta J, Singhal S, eds. Myeloma. London: Martin Dunitz; 2002:327-347.
-
(2002)
Myeloma
, pp. 327-347
-
-
Singhal, S.1
-
7
-
-
0012905046
-
Waldenström's macroglobulinemia
-
Mehta J, Singhal S, eds. London:. Martin Dunitz
-
Dimopoulos MA. Waldenström's macroglobulinemia. In: Mehta J, Singhal S, eds. Myeloma. London: Martin Dunitz; 2002:466-480.
-
(2002)
Myeloma
, pp. 466-480
-
-
Dimopoulos, M.A.1
-
8
-
-
0028362802
-
Bone marrow angiogenesis and progression in multiple myeloma
-
Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87:503-508.
-
(1994)
Br. J. Haematol.
, vol.87
, pp. 503-508
-
-
Vacca, A.1
Ribatti, D.2
Roncali, L.3
-
9
-
-
0032748385
-
Antitumor activity of thalidomide in refractory multiple myeloma
-
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
-
(1999)
N. Engl. J. Med.
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Desikan, R.3
-
10
-
-
0034116457
-
Frequent good partial remissions from thalidomide including best responses ever in patients with advanced refractory and relapsed multiple myeloma
-
Juliusson G, Gelsing F, Toresson I, et al. Frequent good partial remissions from thalidomide including best responses ever in patients with advanced refractory and relapsed multiple myeloma. Br J Haematol 2000; 109:89-96.
-
(2000)
Br. J. Haematol.
, vol.109
, pp. 89-96
-
-
Juliusson, G.1
Gelsing, F.2
Toresson, I.3
-
11
-
-
0034014693
-
Therapy with thalidomide in refractory multiple myeloma patient - The revival of an old drug
-
Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patient - the revival of an old drug. Br J Haematol 2000; 108:391-393.
-
(2000)
Br. J. Haematol.
, vol.108
, pp. 391-393
-
-
Kneller, A.1
Raanani, P.2
Hardan, I.3
-
12
-
-
0034585033
-
Thalidomide in patients with advanced multiple myeloma
-
Yakoub-Agha I, Moreau P, Leyvraz S, et al. Thalidomide in patients with advanced multiple myeloma. Hematol J 2000; 1:186-189.
-
(2000)
Hematol. J.
, vol.1
, pp. 186-189
-
-
Yakoub-Agha, I.1
Moreau, P.2
Leyvraz, S.3
-
13
-
-
0035880229
-
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
-
Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98:492-494.
-
(2001)
Blood
, vol.98
, pp. 492-494
-
-
Barlogie, B.1
Desikan, R.2
Eddlemon, P.3
-
14
-
-
0035211881
-
Novel therapies targeting the myeloma cell and its bone marrow pie microenvironment
-
Hideshima T, Chauban D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow pie microenvironment. Semin Oncol 2001; 28:607-612.
-
(2001)
Semin. Oncol.
, vol.28
, pp. 607-612
-
-
Hideshima, T.1
Chauban, D.2
Podar, K.3
-
15
-
-
0034885073
-
Thalidomide in the management of multiple myeloma
-
Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol 2001; 38:250-259.
-
(2001)
Semin. Hematol.
, vol.38
, pp. 250-259
-
-
Barlogie, B.1
Zangari, M.2
Spencer, T.3
-
16
-
-
0034995376
-
Thalidomide in multiple myeloma: Lack of response of soft-tissue plasmacytomas
-
Bladé J, Perales M, Rosiñol L, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 113:422-424.
-
(2001)
Br. J. Haematol.
, vol.113
, pp. 422-424
-
-
Bladé, J.1
Perales, M.2
Rosiñol, L.3
-
17
-
-
0034861712
-
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma
-
Avigdor A, Raanani P, Levi I, et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 2001; 42:683-687.
-
(2001)
Leuk. Lymphoma
, vol.42
, pp. 683-687
-
-
Avigdor, A.1
Raanani, P.2
Levi, I.3
-
18
-
-
0035881040
-
Treatment of Waldenström's macroglobulinemia with thalidomide
-
Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenström's macroglobulinemia with thalidomide. J Clin Oncol 2001; 19:3596-3601.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 3596-3601
-
-
Dimopoulos, M.A.1
Zomas, A.2
Viniou, N.A.3
-
19
-
-
0037359277
-
Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis
-
Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis. Clin Lymphoma 2003; 3:241-246.
-
(2003)
Clin. Lymphoma
, vol.3
, pp. 241-246
-
-
Seldin, D.C.1
Choufani, E.B.2
Dember, L.M.3
-
20
-
-
0037097843
-
Autologous stem cell transplantation for primary systemic amyloidosis
-
Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99:4276-4282.
-
(2002)
Blood
, vol.99
, pp. 4276-4282
-
-
Comenzo, R.L.1
Gertz, M.A.2
-
21
-
-
0030895545
-
A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
-
Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202-1207.
-
(1997)
N. Engl. J. Med.
, vol.336
, pp. 1202-1207
-
-
Kyle, R.A.1
Gertz, M.A.2
Greipp, P.R.3
|